Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
1699 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Prostate Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H2 2016, provides an overview of the Prostate Cancer (Oncology) pipeline landscape. Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 91, 98, 4, 231, 32 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 10, 58 and 23 molecules, respectively. Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 14 Prostate Cancer Overview 15 Therapeutics Development 16 Prostate Cancer - Therapeutics under Development by Companies 18 Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 41 Prostate Cancer - Pipeline Products Glance 46 Prostate Cancer - Products under Development by Companies 50 Prostate Cancer - Products under Investigation by Universities/Institutes 82 Prostate Cancer - Companies Involved in Therapeutics Development 89 Prostate Cancer - Therapeutics Assessment 370 Drug Profiles 404 Prostate Cancer - Dormant Projects 1571 Prostate Cancer - Discontinued Products 1619 Prostate Cancer - Product Development Milestones 1629 Appendix 1639
List of Tables
Number of Products under Development for Prostate Cancer, H2 2016 75 Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2016 76 Number of Products under Development by Companies, H2 2016 77 Number of Products under Development by Companies, H2 2016 (Contd..1) 78 Number of Products under Development by Companies, H2 2016 (Contd..2) 79 Number of Products under Development by Companies, H2 2016 (Contd..3) 80 Number of Products under Development by Companies, H2 2016 (Contd..4) 81 Number of Products under Development by Companies, H2 2016 (Contd..5) 82 Number of Products under Development by Companies, H2 2016 (Contd..6) 83 Number of Products under Development by Companies, H2 2016 (Contd..7) 84 Number of Products under Development by Companies, H2 2016 (Contd..8) 85 Number of Products under Development by Companies, H2 2016 (Contd..9) 86 Number of Products under Development by Companies, H2 2016 (Contd..10) 87 Number of Products under Development by Companies, H2 2016 (Contd..11) 88 Number of Products under Development by Companies, H2 2016 (Contd..12) 89 Number of Products under Development by Companies, H2 2016 (Contd..13) 90 Number of Products under Development by Companies, H2 2016 (Contd..14) 91 Number of Products under Development by Companies, H2 2016 (Contd..15) 92 Number of Products under Development by Companies, H2 2016 (Contd..16) 93 Number of Products under Development by Companies, H2 2016 (Contd..17) 94 Number of Products under Development by Companies, H2 2016 (Contd..18) 95 Number of Products under Development by Companies, H2 2016 (Contd..19) 96 Number of Products under Development by Companies, H2 2016 (Contd..20) 97 Number of Products under Development by Companies, H2 2016 (Contd..21) 98 Number of Products under Development by Companies, H2 2016 (Contd..22) 99 Number of Products under Investigation by Universities/Institutes, H2 2016 100 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 101 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 102 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 103 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 104 Comparative Analysis by Late Stage Development, H2 2016 105 Comparative Analysis by Clinical Stage Development, H2 2016 106 Comparative Analysis by Early Stage Development, H2 2016 107 Comparative Analysis by Unknown Stage Development, H2 2016 108 Products under Development by Companies, H2 2016 109 Products under Development by Companies, H2 2016 (Contd..1) 110 Products under Development by Companies, H2 2016 (Contd..2) 111 Products under Development by Companies, H2 2016 (Contd..3) 112 Products under Development by Companies, H2 2016 (Contd..4) 113 Products under Development by Companies, H2 2016 (Contd..5) 114 Products under Development by Companies, H2 2016 (Contd..6) 115 Products under Development by Companies, H2 2016 (Contd..7) 116 Products under Development by Companies, H2 2016 (Contd..8) 117 Products under Development by Companies, H2 2016 (Contd..9) 118 Products under Development by Companies, H2 2016 (Contd..10) 119 Products under Development by Companies, H2 2016 (Contd..11) 120 Products under Development by Companies, H2 2016 (Contd..12) 121 Products under Development by Companies, H2 2016 (Contd..13) 122 Products under Development by Companies, H2 2016 (Contd..14) 123 Products under Development by Companies, H2 2016 (Contd..15) 124 Products under Development by Companies, H2 2016 (Contd..16) 125 Products under Development by Companies, H2 2016 (Contd..17) 126 Products under Development by Companies, H2 2016 (Contd..18) 127 Products under Development by Companies, H2 2016 (Contd..19) 128 Products under Development by Companies, H2 2016 (Contd..20) 129 Products under Development by Companies, H2 2016 (Contd..21) 130 Products under Development by Companies, H2 2016 (Contd..22) 131 Products under Development by Companies, H2 2016 (Contd..23) 132 Products under Development by Companies, H2 2016 (Contd..24) 133 Products under Development by Companies, H2 2016 (Contd..25) 134 Products under Development by Companies, H2 2016 (Contd..26) 135 Products under Development by Companies, H2 2016 (Contd..27) 136 Products under Development by Companies, H2 2016 (Contd..28) 137 Products under Development by Companies, H2 2016 (Contd..29) 138 Products under Development by Companies, H2 2016 (Contd..30) 139 Products under Development by Companies, H2 2016 (Contd..31) 140 Products under Investigation by Universities/Institutes, H2 2016 141 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 142 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 143 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 144 Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 145 Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 146 Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 147 Prostate Cancer - Pipeline by 4SC AG, H2 2016 148 Prostate Cancer - Pipeline by AB Science SA, H2 2016 149 Prostate Cancer - Pipeline by AbbVie Inc, H2 2016 150 Prostate Cancer - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 151 Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corp, H2 2016 152 Prostate Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016 153 Prostate Cancer - Pipeline by Addex Therapeutics Ltd, H2 2016 154 Prostate Cancer - Pipeline by Aduro BioTech Inc, H2 2016 155 Prostate Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016 156 Prostate Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016 157 Prostate Cancer - Pipeline by Advantagene Inc, H2 2016 158 Prostate Cancer - Pipeline by Advaxis Inc, H2 2016 159 Prostate Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 160 Prostate Cancer - Pipeline by Aeolus Pharmaceuticals Inc, H2 2016 161 Prostate Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016 162 Prostate Cancer - Pipeline by Aileron Therapeutics Inc, H2 2016 163 Prostate Cancer - Pipeline by Akshaya Bio Inc, H2 2016 164 Prostate Cancer - Pipeline by Alchemia Ltd, H2 2016 165 Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016 166 Prostate Cancer - Pipeline by Alissa Pharma, H2 2016 167 Prostate Cancer - Pipeline by Almac Discovery Ltd, H2 2016 168 Prostate Cancer - Pipeline by Ambrx Inc, H2 2016 169 Prostate Cancer - Pipeline by American Gene Technologies International Inc, H2 2016 170 Prostate Cancer - Pipeline by Amgen Inc, H2 2016 171 Prostate Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016 172 Prostate Cancer - Pipeline by AndroScience Corp, H2 2016 173 Prostate Cancer - Pipeline by AnGes MG Inc, H2 2016 174 Prostate Cancer - Pipeline by AntiCancer Inc, H2 2016 175 Prostate Cancer - Pipeline by Antigen Express Inc, H2 2016 176 Prostate Cancer - Pipeline by Antisense Therapeutics Ltd, H2 2016 177 Prostate Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016 178 Prostate Cancer - Pipeline by Apcure SAS, H2 2016 179 Prostate Cancer - Pipeline by Aphios Corp, H2 2016 180 Prostate Cancer - Pipeline by APIM Therapeutics AS, H2 2016 181 Prostate Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016 182 Prostate Cancer - Pipeline by Aptose Biosciences Inc, H2 2016 183 Prostate Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 184 Prostate Cancer - Pipeline by Armour Therapeutics Inc, H2 2016 185 Prostate Cancer - Pipeline by Arno Therapeutics Inc, H2 2016 186 Prostate Cancer - Pipeline by ArQule Inc, H2 2016 187 Prostate Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 188 Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016 189 Prostate Cancer - Pipeline by Arvinas Inc, H2 2016 190 Prostate Cancer - Pipeline by Asana BioSciences LLC, H2 2016 191 Prostate Cancer - Pipeline by Astellas Pharma Inc, H2 2016 192 Prostate Cancer - Pipeline by Asterias Biotherapeutics Inc, H2 2016 193 Prostate Cancer - Pipeline by AstraZeneca Plc, H2 2016 194 Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 195 Prostate Cancer - Pipeline by Aura Biosciences Inc, H2 2016 196 Prostate Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 197 Prostate Cancer - Pipeline by Avipep Pty Ltd, H2 2016 198 Prostate Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016 199 Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 200 Prostate Cancer - Pipeline by Bayer AG, H2 2016 201 Prostate Cancer - Pipeline by BeiGene Ltd, H2 2016 202 Prostate Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2016 203 Prostate Cancer - Pipeline by BHR Pharma LLC, H2 2016 204 Prostate Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 205 Prostate Cancer - Pipeline by Biotest AG, H2 2016 206 Prostate Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2016 207 Prostate Cancer - Pipeline by Blirt SA, H2 2016 208 Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 209 Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 210 Prostate Cancer - Pipeline by Camurus AB, H2 2016 211 Prostate Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2016 212 Prostate Cancer - Pipeline by CEL-SCI Corp, H2 2016 213 Prostate Cancer - Pipeline by Celgene Corp, H2 2016 214 Prostate Cancer - Pipeline by CellCentric Ltd, H2 2016 215 Prostate Cancer - Pipeline by Cellceutix Corp, H2 2016 216 Prostate Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 217 Prostate Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016 218 Prostate Cancer - Pipeline by Cellmid Ltd, H2 2016 219 Prostate Cancer - Pipeline by Celprogen Inc, H2 2016 220 Prostate Cancer - Pipeline by Chamaeleo Pharma NV, H2 2016 221 Prostate Cancer - Pipeline by Chiome Bioscience Inc, H2 2016 222 Prostate Cancer - Pipeline by Clovis Oncology Inc, H2 2016 223 Prostate Cancer - Pipeline by CohBar Inc, H2 2016 224 Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H2 2016 225 Prostate Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016 226 Prostate Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 227 Prostate Cancer - Pipeline by Crescendo Biologics Ltd, H2 2016 228 Prostate Cancer - Pipeline by Curevac AG, H2 2016 229 Prostate Cancer - Pipeline by CytoVac A/S, H2 2016 230 Prostate Cancer - Pipeline by CZ BioMed Corp, H2 2016 231 Prostate Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 232 Prostate Cancer - Pipeline by DEKK-TEC Inc, H2 2016 233 Prostate Cancer - Pipeline by DexTech Medical AB, H2 2016 234 Prostate Cancer - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 235 Prostate Cancer - Pipeline by DNJ Pharma Inc, H2 2016 236 Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2016 237 Prostate Cancer - Pipeline by DormaTarg Inc, H2 2016 238 Prostate Cancer - Pipeline by Eisai Co Ltd, H2 2016 239 Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2016 240 Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H2 2016 241 Prostate Cancer - Pipeline by EndoCeutics Inc, H2 2016 242 Prostate Cancer - Pipeline by Endocyte Inc, H2 2016 243 Prostate Cancer - Pipeline by EntreChem SL, H2 2016 244 Prostate Cancer - Pipeline by EOS Biosciences Inc, H2 2016 245 Prostate Cancer - Pipeline by Errant Gene Therapeutics LLC, H2 2016 246 Prostate Cancer - Pipeline by Esperance Pharmaceuticals Inc, H2 2016 247 Prostate Cancer - Pipeline by ESSA Pharma Inc, H2 2016 248 Prostate Cancer - Pipeline by Eureka Therapeutics Inc, H2 2016 249 Prostate Cancer - Pipeline by Evgen Pharma Plc, H2 2016 250 Prostate Cancer - Pipeline by Exonate Ltd, H2 2016 251 Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 252 Prostate Cancer - Pipeline by Ferring International Center SA, H2 2016 253 Prostate Cancer - Pipeline by Foresee Pharmaceuticals LLC, H2 2016 254 Prostate Cancer - Pipeline by Fountain Biopharma Inc, H2 2016 255 Prostate Cancer - Pipeline by Fujifilm Corp, H2 2016 256 Prostate Cancer - Pipeline by G1 Therapeutics Inc, H2 2016 257 Prostate Cancer - Pipeline by Galectin Therapeutics Inc, H2 2016 258 Prostate Cancer - Pipeline by Genelux Corp, H2 2016 259 Prostate Cancer - Pipeline by Genentech Inc, H2 2016 260 Prostate Cancer - Pipeline by GeneSegues Inc, H2 2016 261 Prostate Cancer - Pipeline by Genmab A/S, H2 2016 262 Prostate Cancer - Pipeline by Gilead Sciences Inc, H2 2016 263 Prostate Cancer - Pipeline by Glactone Pharma AB, H2 2016 264 Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 265 Prostate Cancer - Pipeline by GlycoMimetics Inc, H2 2016 266 Prostate Cancer - Pipeline by GP Pharm SA, H2 2016 267 Prostate Cancer - Pipeline by GTx Inc, H2 2016 268 Prostate Cancer - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016 269 Prostate Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 270 Prostate Cancer - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2016 271 Prostate Cancer - Pipeline by Hybrigenics SA, H2 2016 272 Prostate Cancer - Pipeline by IC-MedTech Inc, H2 2016 273 Prostate Cancer - Pipeline by Ideaya Biosciences Inc, H2 2016 274 Prostate Cancer - Pipeline by IGF Oncology LLC, H2 2016 275 Prostate Cancer - Pipeline by Ignyta Inc, H2 2016 276 Prostate Cancer - Pipeline by Ildong Pharmaceutical Co Ltd, H2 2016 277 Prostate Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2016 278 Prostate Cancer - Pipeline by Immuneed AB, H2 2016 279 Prostate Cancer - Pipeline by Immunocore Ltd, H2 2016 280 Prostate Cancer - Pipeline by ImmunoFrontier Inc, H2 2016 281 Prostate Cancer - Pipeline by Immunomedics Inc, H2 2016 282 Prostate Cancer - Pipeline by Immupharma Plc, H2 2016 283 Prostate Cancer - Pipeline by Incanthera Ltd, H2 2016 284 Prostate Cancer - Pipeline by Incuron LLC, H2 2016 285 Prostate Cancer - Pipeline by Inflection Biosciences Ltd, H2 2016 286 Prostate Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2 2016 287
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
